Hookipa Pharma Stock Analysis
| HOOK Stock | USD 1.06 0.03 2.91% |
IPO Date 18th of April 2019 | 200 Day MA 1.0352 | 50 Day MA 0.9279 | Beta 0.89 |
Hookipa Pharma holds a debt-to-equity ratio of 0.052. At this time, Hookipa Pharma's Short and Long Term Debt is quite stable compared to the past year. Long Term Debt To Capitalization is expected to rise to 0.01 this year, although the value of Short and Long Term Debt Total will most likely fall to about 748.1 K. Hookipa Pharma's financial risk is the risk to Hookipa Pharma stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Hookipa Pharma's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Hookipa Pharma's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Hookipa Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Hookipa Pharma's stakeholders.
For many companies, including Hookipa Pharma, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Hookipa Pharma, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Hookipa Pharma's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.4428 | Enterprise Value Ebitda 0.4569 | Price Sales 1.3977 | Shares Float 12.3 M | Wall Street Target Price 2 |
Hookipa Pharma is undervalued with Real Value of 1.24 and Target Price of 2.0. The main objective of Hookipa Pharma stock analysis is to determine its intrinsic value, which is an estimate of what Hookipa Pharma is worth, separate from its market price. There are two main types of Hookipa Pharma's stock analysis: fundamental analysis and technical analysis.
The Hookipa Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. Hookipa Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. Hookipa Pharma recorded a loss per share of 4.83. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 10th of July 2024. HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company was incorporated in 2011 and is headquartered in New York, New York. Hookipa Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 131 people. To learn more about Hookipa Pharma call Joern Aldag at 431 890 6360 or check out https://www.hookipapharma.com.Hookipa Pharma Quarterly Total Revenue |
|
Hookipa Pharma Investment Alerts
| Hookipa Pharma has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 43.95 M. Net Loss for the year was (43.5 M) with loss before overhead, payroll, taxes, and interest of (50.47 M). | |
| Hookipa Pharma currently holds about 117.92 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hookipa Pharma has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Hooked Protocol Hits 24 Hour Trading Volume of 3.06 Million |
Hookipa Largest EPS Surprises
Earnings surprises can significantly impact Hookipa Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-22 | 2023-12-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2022-11-14 | 2022-09-30 | -0.28 | -0.25 | 0.03 | 10 | ||
2023-11-09 | 2023-09-30 | -0.21 | -0.17 | 0.04 | 19 |
Hookipa Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-06-30 | 17 K | Northern Trust Corp | 2025-06-30 | 15.7 K | Blackrock Inc | 2025-06-30 | 12.2 K | Boothbay Fund Management, Llc | 2025-06-30 | 11.7 K | Tower Research Capital Llc | 2025-06-30 | 3.5 K | Jpmorgan Chase & Co | 2025-06-30 | 815 | Advisor Group Holdings, Inc. | 2025-06-30 | 500 | Bank Of America Corp | 2025-06-30 | 481 | Simplex Trading, Llc | 2025-06-30 | 341 | Baker Bros Advisors Lp | 2025-06-30 | 812.8 K | Siren, L.l.c. | 2025-06-30 | 566.6 K |
Hookipa Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.07 M.Hookipa Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (1.02) | (1.07) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.98) | (1.03) |
Management Efficiency
Hookipa Pharma has return on total asset (ROA) of (0.452) % which means that it has lost $0.452 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0579) %, meaning that it created substantial loss on money invested by shareholders. Hookipa Pharma's management efficiency ratios could be used to measure how well Hookipa Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.64. The value of Return On Capital Employed is expected to slide to -1.07. At this time, Hookipa Pharma's Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 7.7 M this year, although the value of Total Current Liabilities will most likely fall to about 25.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.68 | 3.49 | |
| Tangible Book Value Per Share | 3.68 | 3.49 | |
| Enterprise Value Over EBITDA | 0.38 | 0.40 | |
| Price Book Value Ratio | 0.44 | 0.64 | |
| Enterprise Value Multiple | 0.38 | 0.40 | |
| Price Fair Value | 0.44 | 0.64 | |
| Enterprise Value | -15.6 M | -14.9 M |
The management team at Hookipa Pharma has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Technical Drivers
As of the 11th of February 2026, Hookipa Pharma retains the Downside Deviation of 1.96, risk adjusted performance of 0.1397, and Market Risk Adjusted Performance of (0.46). Hookipa Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Hookipa Pharma Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Hookipa Pharma price series with the more recent values given greater weights.
Hookipa Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hookipa Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hookipa Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hookipa Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hookipa Pharma Outstanding Bonds
Hookipa Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Hookipa Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Hookipa bonds can be classified according to their maturity, which is the date when Hookipa Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Hookipa Pharma Predictive Daily Indicators
Hookipa Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Hookipa Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Hookipa Pharma Forecast Models
Hookipa Pharma's time-series forecasting models are one of many Hookipa Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hookipa Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Hookipa Pharma Bond Ratings
Hookipa Pharma financial ratings play a critical role in determining how much Hookipa Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Hookipa Pharma's borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (2.64) | Unlikely Manipulator | View |
Hookipa Pharma Debt to Cash Allocation
Hookipa Pharma currently holds 875 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Hookipa Pharma has a current ratio of 5.37, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Hookipa Pharma's use of debt, we should always consider it together with its cash and equity.Hookipa Pharma Total Assets Over Time
Hookipa Pharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Hookipa Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Hookipa Pharma Debt Ratio | 1.16 |
Hookipa Pharma Corporate Bonds Issued
Hookipa Short Long Term Debt Total
Short Long Term Debt Total |
|
About Hookipa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Hookipa Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Hookipa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Hookipa Pharma. By using and applying Hookipa Stock analysis, traders can create a robust methodology for identifying Hookipa entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.89) | (0.94) | |
| Operating Profit Margin | (1.05) | (1.11) | |
| Net Loss | (0.89) | (0.94) | |
| Gross Profit Margin | 0.84 | 0.89 |
Current Hookipa Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Hookipa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Hookipa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 2.0 | Buy | 3 | Odds |
Most Hookipa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Hookipa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Hookipa Pharma, talking to its executives and customers, or listening to Hookipa conference calls.
Hookipa Stock Analysis Indicators
Hookipa Pharma stock analysis indicators help investors evaluate how Hookipa Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Hookipa Pharma shares will generate the highest return on investment. By understating and applying Hookipa Pharma stock analysis, traders can identify Hookipa Pharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 117.5 M | |
| Common Stock Shares Outstanding | 12.5 M | |
| Total Stockholder Equity | 51.2 M | |
| Total Cashflows From Investing Activities | -194 K | |
| Tax Provision | -106 K | |
| Property Plant And Equipment Net | 1.1 M | |
| Cash And Short Term Investments | 39.7 M | |
| Cash | 39.7 M | |
| Accounts Payable | 8.7 M | |
| Net Debt | -38.8 M | |
| 50 Day M A | 0.9279 | |
| Total Current Liabilities | 24.7 M | |
| Other Operating Expenses | 95.4 M | |
| Non Current Assets Total | 1.9 M | |
| Non Currrent Assets Other | 712 K | |
| Stock Based Compensation | 2 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. Market participants price Hookipa higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Hookipa Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.83) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
Investors evaluate Hookipa Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Hookipa Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Hookipa Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Hookipa Pharma's market price signifies the transaction level at which participants voluntarily complete trades.